Oncology Value Watchdog Report: ASCO 2017: Spotlight on Value

( http://pages.zs.com/Oncology-Value-Watchdog-Report-ASCO-2017.html )


> Download ( http://pages.zs.com/Oncology-Value-Watchdog-Report-ASCO-2017.html )

ASCO 2017 covered several topics related to value in oncology, including sustained discussion regarding biosimilars, drug pricing, pathways and value frameworks, as well as coverage of the impacts of the Medicare Access and CHIP Reauthorization Act (MACRA) provisions among oncology providers. Learnings regarding MACRA are of particular note since the quality payment program reporting period officially began in 2017, marking the beginning of a progressive change to physician reimbursement under Medicare FFS, the largest payer in oncology. In addition, ASCO participants also shared details regarding implementation of the Oncology Care Model (OCM) which lend insight into the challenges and future direction of participation in this advanced payment model (APM).


About the Expert





Christina Corridon is an Associate Principal in the Boston office and a leader in the ZS Oncology Practice. She has over a decade experience working in the pharmaceutical and biotech industries, with specific expertise in oncology and biosimilars. During her consulting career she has worked on US and global projects spanning commercialization strategy including launch strategy and planning, go-to market strategy, commercial models, marketing strategy and brand planning. Christina has an MPH in Health Policy and Management from the UCLA Fielding School of Public Health and an MBA from the Stern School of Business at New York University focused in Marketing. Christina completed her BA at Cornell University.